Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Checkpoint kinase 1 inhibitors (CHK1i) demonstrate efficacy in certain cancers but sensitive tumor types and mechanisms remain unclear.
• Understanding CHK1i response requires identifying sensitive populations and downstream effectors.

Purpose of the Study:

• To identify tumor types sensitive to CHK1i.
• To elucidate the downstream molecular mechanisms of CHK1i action in hematologic malignancies (HMs).
• To evaluate a novel CHK1 inhibitor, PY34, in HMs.

Main Methods:

• Analysis of Genomics of Drug Sensitivity in Cancer (GDSC) and DepMap databases.
• In vitro and in vivo studies using a selective CHK1 inhibitor (PY34) on HM cell lines.
• Transcriptomic profiling and c-Myc signaling pathway analysis.
• Correlation analysis between c-Myc levels and sensitivity in HM cell lines and patient-derived cells (PDCs).

Main Results:

• Hematologic malignancies (HMs) exhibit relative sensitivity to CHK1i or CHK1 knockdown.
• The novel CHK1i, PY34, demonstrated potent anti-HM effects in vitro and in vivo.
• Downregulation of c-Myc and its signaling pathway was a common response in sensitive HM cell lines to PY34.
• Overexpression of c-Myc partially rescued the anti-cancer effects of PY34.
• Significant correlations were found between c-Myc downregulation and PY34 sensitivity in HM cell lines and PDCs.

Conclusions:

• Hematologic malignancies (HMs) are more sensitive to CHK1i than solid tumors.
• c-Myc downregulation is a key indicator of CHK1i efficacy in HMs.
• Targeting c-Myc signaling may enhance CHK1i-based therapies for hematologic malignancies.